New-generation 5-HT₄ receptor agonists: potential for treatment of gastrointestinal motility disorders

Bibliography

• Camilleri M. Serotonergic drugs: emerging therapies for IBS. In: Camilleri M, Spiller RC, editors, Irritable Bowel Syndrome. WB. Saunders, Elsevier Sciences Limited, Edinburgh; 2002. p. 179-90
   Google Scholar
• Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132:397-414
   PubMed Web of Science ®Google Scholar
• Manabe N, Wong BS, Camilleri M, Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Bredenoord AJ, Chiari HJ, Camilleri M, Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003;1:264-72
   PubMed Web of Science ®Google Scholar
• Tack J, Jones MP, Karamanolis G, Symptom pattern and pathophysiological correlates of weight loss in tertiary-referred functional dyspepsia. Neurogastroenterol Motil 2010;22:29-35
   PubMed Web of Science ®Google Scholar
• Quartero AO, de Wit NJ, Lodder AC, Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998;43:2028-33
   PubMed Web of Science ®Google Scholar
• Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002;71:533-54
   PubMed Web of Science ®Google Scholar
• Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000;95:2698-709
   PubMed Web of Science ®Google Scholar
• Gershon MD. Review article: serotonin receptors and transporters – roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004;20:3-14
   PubMed Web of Science ®Google Scholar
• Tonini M, Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 2006;24:59-69
   PubMed Web of Science ®Google Scholar
• Moro E, Crema F, De Ponti F, Frigo G. Triptans and gastric accommodation: pharmacological and therapeutic aspects. Dig Liver Dis 2004;36:85-92
   PubMedGoogle Scholar
• Storr M, Schusdziarra V, Allescher HD. Inhibition of small conductance K+-channels attenuated melatonin-induced relaxation of serotonin-contracted rat gastric fundus. Can J Physiol Pharmacol 2000;78:799-806
   PubMed Web of Science ®Google Scholar
• Hegde SS, Eglen RM. Peripheral 5-HT4 receptors. FASEB J 1996;10:1398-407
   PubMed Web of Science ®Google Scholar
• Maddern GJ, Jamieson GG, Myers JC, Collins PJ. Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease. Gut 1991;32:470-4
   PubMed Web of Science ®Google Scholar
• Pehlivanov N, Sarosiek I, Whitman R, Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2002;16:743-7
   PubMed Web of Science ®Google Scholar
• Tack J, Broeckaert D, Coulie B, Janssens J. The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharmacol Ther 1998;12:761-6
   PubMed Web of Science ®Google Scholar
• Ruth M, Hamelin B, Röhss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998;12:35-40
   PubMed Web of Science ®Google Scholar
• Kim HS. 5-Hydroxytryptamine4 receptor agonists and colonic motility. J Smooth Muscle Res 2009;45:25-9
   PubMedGoogle Scholar
• Kim HS, Choi EJ, Park H. The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil 2008;20:169-76
   PubMed Web of Science ®Google Scholar
• Prather CM, Camilleri M, Zinsmeister AR, Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-8
   PubMed Web of Science ®Google Scholar
• Quigley EM, Wald A, Fidelholtz J, Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies. Clin Gastroenterol Hepatol 2006;4:605-13
   PubMed Web of Science ®Google Scholar
• Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2007;4:CD003960
   PubMed Web of Science ®Google Scholar
• Ducic I, Ko CM, Shuba Y, Comparative effects of loratadine and terfenadine on cardiac K+ channels. J Cardiovasc Pharmacol 1997;30:42-54
   PubMed Web of Science ®Google Scholar
• Ripden DM. Antiarrhythmic drugs. In: Topol EJ, editor, Comprehensive cardiovascular medicine. Lippincott Raven Publishers, Philadelphia; 1998. p. 2053-70
   Google Scholar
• Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-80
   PubMed Web of Science ®Google Scholar
• Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995;269:92-5
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Lefebvre RA, Schuurkes JAJ. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20:99-112
   PubMed Web of Science ®Google Scholar
• Mohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997;273:H2534-8
   PubMed Web of Science ®Google Scholar
• Nilsson T, Longmore J, Shaw D, Characterization of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999;372:49-56
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Reekers M, Bax WA, Saxena PR. Human isolated coronary artery contraction to sumatriptan characterized by the selective 5-HT1B/1D receptor antagonist GR55562. Pharmacol Toxicol 2000;86:287-90
   PubMedGoogle Scholar
• Villalón CM, Centurión D. Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch 2007;376:45-63
   PubMed Web of Science ®Google Scholar
• Dumuis A, Sebben M, Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neuron. Naunyn Schmiedebergs Arch 1989;340:403-10
   PubMed Web of Science ®Google Scholar
• Blondel O, Gastineau M, Dahmoune Y, Cloning, expression and pharmacology of four human 5-hydroxytryptamine4 receptor isoforms produced by alternative splicing in the carboxy terminus. J Neurochem 1998;70:2252-61
   PubMed Web of Science ®Google Scholar
• Claeysen S, Faye P, Sebben M, 5-HT4 receptors: cloning and expression of new splice variants. Ann NY Acad Sci 1998;861:49-56
   PubMed Web of Science ®Google Scholar
• Sanger GJ. Translating 5-HT receptor pharmacology. Neurogastroenterol Motil 2009;21:1235-8
   PubMed Web of Science ®Google Scholar
• Bockaert J, Claeysen S, Compan V, Dumuis A. 5-HT4 receptors. Curr Drug Targets CNS Neurol Disord 2004;3(1):39-51
   PubMedGoogle Scholar
• Briejer MR, Akkermans LMA, Schuurkes JAJ. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995;47:631-51
   PubMed Web of Science ®Google Scholar
• Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA. 5-HT4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol 2000;131:927-32
   PubMed Web of Science ®Google Scholar
• Baxter GS, Craig DA, Clarke DE. 5-hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae. Naunyn Schmeidebergs Arch Pharmacol 1991;343:439-46
   PubMed Web of Science ®Google Scholar
• Kilbinger H, Wolf D. Effects of 5-HT4 receptors stimulation on basal and electrically evoked release of acetylcholine from guinea-pig myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol 1992;345:270-5
   PubMed Web of Science ®Google Scholar
• Kilbinger H, Gebauer A, Haas J, Benzimidazolones and renzapride facilitate acetylcholine release from guinea-pig myenteric plexus via 5-HT4 receptors. Naunyn Schmiedebergs Arch Pharmacol 1995;351:229-36
   PubMed Web of Science ®Google Scholar
• Grider JR, Kuemmerle JF, Jin JG. 5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4/5-HT1P receptors on sensory CGRP neurons. Am J Physiol 1996;270:G778-82
   PubMed Web of Science ®Google Scholar
• Kellum JM, Albuquerque FC, Stoner MC, Harris RP. Stroking human jejunal mucosa induces 5-HT release and Cl-secretion via afferent neurons and 5-HT4 receptors. Am J Physiol 1999;277:G515-20
   PubMed Web of Science ®Google Scholar
• Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998;115:370-80
   PubMed Web of Science ®Google Scholar
• Edwards CA, Holden S, Brown C, Read NW. Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects. Gut 1987;28:13-6
   PubMed Web of Science ®Google Scholar
• Krevsky B, Maurer AH, Malmud LS, Fisher RS. Cisapride accelerates colonic transit in constipated patients with colonic inertia. Am J Gastroenterol 1989;84:882-7
   PubMed Web of Science ®Google Scholar
• Krevsky B, Malmud LS, Maurer AH, The effect of oral cisapride on colonic transit. Aliment Pharmacol Ther 1987;1:293-304
   PubMedGoogle Scholar
• Camilleri M, Malagelada JR, Abell TL, Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989;96:704-12
   PubMed Web of Science ®Google Scholar
• Camilleri M, Brown ML, Malagelada JR. Impaired transit of chyme in chronic intestinal pseudoobstruction. Correction by cisapride. Gastroenterology 1986;91:619-26
   PubMed Web of Science ®Google Scholar
• Degen L, Matzinger D, Merz M, Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:1745-51
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354-60
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44:682-6
   PubMed Web of Science ®Google Scholar
• Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003;67:82-9
   PubMed Web of Science ®Google Scholar
• Nichols T, Beyens G, Ausma J, A double-blind, placebo-controlled, dose-finding trial on the efficacy and safety of prucalopride in patients with chronic constipation. Gut 2008;57(Suppl II):A283
   Google Scholar
• Miner PJ, Nichols T, Silvers D, The efficacy and safety of prucalopride in patients with chronic constipation. Gastroenterology 1999;116:A1043
   PubMed Web of Science ®Google Scholar
• Felt-Bersma R, Bouchoucha M, Wurzer H, Effects of a new enterokinetic drug, prucalopride, on symptoms of patients with chronic constipation: a double-blind, placebo-controlled, multicenter study in Europe. Gastroenterology 1999;116:A1043
   PubMed Web of Science ®Google Scholar
• Winter H, Ausma J, Vandeplassche L. An open label follow-up study of prucalopride solution in pediatric subjects with functional fecal retention. Gastroenterology 2009;116:A1043
   Google Scholar
• Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-54
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315-28
   PubMed Web of Science ®Google Scholar
• Tack J, van Outryve M, Beyens G, Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357-65
   PubMed Web of Science ®Google Scholar
• Kobert KA, Brattelid T, Levy FO, Kaumann AJ. Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants. Naunyn Schmiedebergs Arch Pharmacol 2005;371:473-9
   PubMed Web of Science ®Google Scholar
• De Maeyer J, Straetemans R, Schuurkes J, Lefebvre R. Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development. Br J Pharmacol 2006;147:140-57
   PubMed Web of Science ®Google Scholar
• Bach T, Syversveen T, Kvingedal A, 5 HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Nauuyn Schmiedebergs Arch Pharmacol 2001;363:146-60
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Schuurkes JA, Lefebvre RA. Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach. Br J Pharmacol 2009;156:362-76
   PubMed Web of Science ®Google Scholar
• Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol 2007;554:98-105
   PubMed Web of Science ®Google Scholar
• Camilleri M, Beyens G, Kerstens R, Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21:1256-e117
   PubMed Web of Science ®Google Scholar
• Sloots CE, Poen AC, Kerstens R, Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002;16:759-67
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16:1347-56
   PubMed Web of Science ®Google Scholar
• Camilleri M, Vazquez-Roque MI, Burton D, Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007;19:30-8
   PubMed Web of Science ®Google Scholar
• Dennis D, Palme M, Irwin I, ATI-7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dog. Gastroenterology 2004;126:A641
   PubMedGoogle Scholar
• Beattie DT, Smith JA, Marquess D, The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol 2004;143:549-60
   PubMed Web of Science ®Google Scholar
• Smith J, Beattie DT, Cuthbert AW, TD-5108, a selective, high intrinsic activity 5-HT4 receptor agonist – in vitro profile at human recombinant 5-HT4 receptor splice variant and human isolated colon. Gastroenterology 2007;132:A687
   PubMed Web of Science ®Google Scholar
• Beattie DT, Armstrong SR, Shaw JP, The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008;378:139-47
   PubMed Web of Science ®Google Scholar
• Manini ML, Camilleri M, Goldberg M, Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010;22:42-9, e7-8
   PubMed Web of Science ®Google Scholar
• Goldberg MR, Li YP, Pitzer K, TD-5108, a selective 5-HT4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation. Gastroenterology 2008;134:A545
   Web of Science ®Google Scholar
• Goldberg MR, Wong SL, Ganju J, TD-5108, a selective 5-HT4 agonist with high intrinsic activity, shows immediate and sustained prokinetic activity in healthy subjects. Gastroenterology 2007;132:A60
   Web of Science ®Google Scholar